Photo by solenfeyissa from unsplash
Current guidelines recommend methotrexate (MTX) as a glucocorticoid‐sparing agent in patients with polymyalgia rheumatica (PMR) who relapse or suffer glucocorticoid adverse effects, although there is no level 1 evidence to… Click to show full abstract
Current guidelines recommend methotrexate (MTX) as a glucocorticoid‐sparing agent in patients with polymyalgia rheumatica (PMR) who relapse or suffer glucocorticoid adverse effects, although there is no level 1 evidence to support this recommendation.
Keywords:
methotrexate polymyalgia;
polymyalgia rheumatica;
routine rheumatology;
efficacy methotrexate;
rheumatology;
rheumatica routine
Journal Title: Internal Medicine Journal
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Internal Medicine Journal
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!